Arcadia Biosciences (RKDA) Upgraded to Strong Buy: Here's What You Should Know

This agricultural biotechnology trait company is expected to earn -$2.29 per share for the fiscal year ending December 2024, which represents a year-over-year change of 79.2%. Analysts have been steadily raising their estimates for Arcadia Biosciences. Over the past three months, the Zacks Consensus Estimate for the company has increased 54.3%. You can learn more about the Zacks Rank here >>> The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating syste ...